Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 4/20 | 0.59 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.41 |
| ▸ | NCK1 | P16333 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 3/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2025827 | 0.85 | GRN (0.57) | GRNSORT1KDM4EMAPK13MAPK12 | |
| SCHEMBL2028017 | 0.81 | GRN (0.62) | GRNSORT1KDM4EMAPK13MAPK12 | |
| SCHEMBL1600233 | 0.76 | GRN (0.80) | GRNSORT1KDM4EMAPK13MAPK12 | |
| SCHEMBL2081250 | 0.75 | MAP4K4 (0.49) | GRNSORT1BACE1LMNAALDH1A1 | |
| SCHEMBL1646829 | 0.75 | GRN (1.00) | GRNSORT1KDM4EMAPK13MAPK12 | |
| SCHEMBL15485403 | 0.75 | GRN (0.72) | GRNSORT1KDM4EMAPK13MAPK12 | |
| SCHEMBL2084287 | 0.74 | MAPT (0.49) | GRNSORT1MAPK13MAPK12MAPK11 | |
| SCHEMBL18277669 | 0.72 | GRN (0.72) | GRNSORT1KDM4EMAPK13MAPK12 | |
| SCHEMBL16749343 | 0.72 | GRN (0.76) | GRNSORT1KDM4EMAPK13MAPK12 | |
| SCHEMBL2026224 | 0.72 | CYP1A2 (0.50) | KDM4EMAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2942349-A1 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2015-11-11 | — | — | EP | disclosed |
| EP-2942349-A1 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2015-11-11 | — | — | EP | disclosed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| EP-1835934-A2 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | GRN 3968/4885SORT1 3228/4885KDM4E 1665/4885 |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | GRN 3157/4885SORT1 4054/4885KDM4E 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.